Apremilast
Brand Names: Otezla
Methodology & AI Transparency ⓘ
Apremilast Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage otezla:/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Oral ulcers associated with Behçet's Disease ( 1.3 ) Pediatric patients 6 years of age and older with: Active psoriatic arthritis ( 1.1 ) Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for.
- 2 Real-world patient consensus: Tracked across 4 patient dosage logs with a 89% satisfaction benchmark (RxCUI 1492732).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Apremilast include nausea (12%), headache (10.6%), diarrhea (9.3%).
Ask our AI Specialists anything about Apremilast
Apremilast Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage otezla:/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Oral ulcers associated with Behçet's Disease ( 1.3 ) Pediatric patients 6 years of age and older with: Active psoriatic arthritis ( 1.1 ) Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for.
12.1 Mechanism of Action Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.
Systemic exposure to Apremilast reflects ~73% systemic bioavailability (Apremilast) absorption kinetics and phase i/ii hepatic conjugation of apremilast coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 6–13 hours terminal plasma half-life for Apremilast half-life window (peak plasma concentration (tmax) reached 1–4 hours post-dose for apremilast response profile).
Dosing protocols (Kit or 30 mg/1 Tablet, Film Coated or 75 mg/1 Tablet, Film Coated or 20 mg/1 Tablet, Film Coated) balance efficacy (89.00% patient satisfaction across 4 logs) against nausea (12% of reports), headache (10.6% of reports), diarrhea (9.3% of reports), with strict avoidance in 4 contraindications otezla/otezla xr is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation .; known hypersensitivity to apremilast or to any of the excipients in the formulation ( 4 ).
Accelerated hepatic clearance from strong CYP induction may require monitoring for subtherapeutic Apremilast efficacy.
Assess baseline hepatic panels and interacting prescriptions when starting Apremilast (phosphodiesterase 4 inhibitor).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS OTEZLA/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation .
- Known hypersensitivity to apremilast or to any of the excipients in the formulation ( 4 )
Logged Side-Effect Incidence (4 Reports)
Apremilast Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Apremilast)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deucravacitinib in moderate-to-severe plaque psoriasis skin flare-ups: Pooled: What a 1,683-Participant Study Found Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-08-15 • Phase III Randomized Trial | N = 1,683 | 96/100 | PMID 38451052 ↗ |
| New Insights on Apremilast single-drug treatment for long-term treatment of active psoriatic: What a 527-Participant Study Found Apremilast led to sustained PsA efficacy up to 260 weeks and was well tolerated. Rheumatology (Oxford, England) • 2022-03-02 • Phase III Randomized Trial | N = 527 | 93/100 | PMID 34100922 ↗ |
| New Insights on Benefits and safety of piclidenoson in plaque psoriasis skin flare-ups: Results: What a 529-Participant Study Found Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-06-15 • Phase III Randomized Trial | N = 529 | 93/100 | PMID 38279575 ↗ |
| New Insights on Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A: What a 666-Participant Study Found The trial included 666 patients (mean [SD] age, 46.1 [13.4] years; 453 men [68.0%]). JAMA dermatology • 2024-02-01 • Phase III Randomized Trial | N = 666 | 93/100 | PMID 38117487 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. The Journal of rheumatology • 2022-07-15 • Phase III Randomized Trial | N = 126 | 88/100 | PMID 35428720 ↗ |
Apremilast Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $86.3803/unit (~$2591.41/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Apremilast Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Apremilast RxNorm Concept ID | 1492732 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $86.3803 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Apremilast Patient Community, Cohort Filters & Dosage Logs
Deterministic Apremilast reference combining NIH RxNorm (1492732), Medicaid NADAC ($86.3803/unit), and anonymous cohort outcomes (89% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Apremilast community threads and patient logs by age, biological sex, dosage, and treatment duration.